4//SEC Filing
Wesche Holger 4
Accession 0001209191-21-002317
CIK 0001708493other
Filed
Jan 5, 7:00 PM ET
Accepted
Jan 6, 6:25 PM ET
Size
13.5 KB
Accession
0001209191-21-002317
Insider Transaction Report
Form 4
Wesche Holger
Chief Scientific Officer
Transactions
- Exercise/Conversion
Common Stock
2021-01-04$0.60/sh+10,000$6,000→ 62,852 total - Sale
Common Stock
2021-01-04$19.39/sh−3,549$68,828→ 52,852 total - Sale
Common Stock
2021-01-04$17.32/sh−3,100$53,683→ 59,752 total - Sale
Common Stock
2021-01-04$18.30/sh−3,351$61,327→ 56,401 total - Exercise/Conversion
Employee Stock Option (right to buy)
2021-01-04−10,000→ 11,006 totalExercise: $0.60Exp: 2027-01-13→ Common Stock (10,000 underlying)
Footnotes (6)
- [F1]Includes 183 shares acquired under the Employee Stock Purchase Plan on September 30, 2020.
- [F2]The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- [F3]Represents the weighted average sales price per share. The shares sold at prices ranging from $16.8831 to $17.86 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- [F4]Represents the weighted average sales price per share. The shares sold at prices ranging from $17.89 to $18.75 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- [F5]Represents the weighted average sales price per share. The shares sold at prices ranging from $19.00 to $19.78 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- [F6]The stock options are part of a grant that vested and became exercisable as to 25% of the shares subject to the option grant on May 24, 2017, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the options are 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.
Documents
Issuer
Harpoon Therapeutics, Inc.
CIK 0001708493
Entity typeother
Related Parties
1- filerCIK 0001763592
Filing Metadata
- Form type
- 4
- Filed
- Jan 5, 7:00 PM ET
- Accepted
- Jan 6, 6:25 PM ET
- Size
- 13.5 KB